Page 11 - Junshi Bioscience News Today

In India, Drugs for COVID Are Being Tested, Approved in Ways That Should Worry Us 25/05/2021 Representative photo: analuisa gamboa/Unsplash Mumbai: Since the start of the COVID-19 pandemic last year, researchers around the world have evaluated scores of drugs and therapeutic techniques for the disease. Even according to the Clinical Trial Registry of India (CTRI), researchers in the country are testing everything from inhaled camphor and ajwain to Viagra. This may be desperation, giv...

- Toripalimab data will also be featured in ASCO's official press program -SHANGHAI, China, and REDWOOD CITY, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd. ("Junshi Biosciences"

June 3, 2021, 5:00 p.m. Eastern Daylight Time “We are excited that results of JUPITER-02, a Phase 3 clinical trial evaluating toripalimab plus chemotherapy for the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma, have been selected for presentation during ASCO’s plenary session, which traditionally features high-impact studies,” said Dr. Patricia Keegan, Chief Medical Officer of Junshi Biosciences. “Treatment of nasopharyngeal carcinoma, a specific type of head-...

Bookmark of this page has been deleted. Coherus Announces Toripalimab Achieved Primary Endpoints of Progression Free Survival and Overall Survival in Interim Analysis of Phase 3 Clinical Trial in First-Line Esophageal Squamous Cell Carcinoma REDWOOD CITY, Calif., April 23, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. ( CHRS) has received notice from immuno-oncology partner Junshi Biosciences that the Independent Data Monitoring Committee of the JUPITER-06 clinical trial has determined tha...

(1) - BLA submitted with FDAs breakthrough therapy designation - SHANGHAI, China and REDWOOD CITY, Calif., March 03, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd. ("Junshi Biosciences", HKEX: 1877; SSE: 688180) and Coherus Biosciences, Inc. ("Coherus", Nasdaq: CHRS) announced today the initiation of the rolling submission of the Biologics License Application ("BLA") for toripalimab to the U.S. Food and Drug Administration ("FDA") for the treatment of recurrent or metastatic n...

Feb 2, 2021 10:50am Coherus BioSciences is shelling out $150 million upfront for U.S. and Canadian rights to Junshi Biosciences’ PD-1 inhibitor toripalimab. (Kritchanut/iStock/Getty Images Plus/Getty Images) On the heels of Novartis licensing BeiGene’s tislelizumab, another China-made PD-1 inhibitor has found itself a new U.S. collaborator in a company that’s just pivoting to immuno-oncology. Coherus BioSciences is shelling out $150 million upfront for U.S. and Canadian rights to Junshi B...

Share this article Share this article BOSTON and BEIJING, Feb. 3, 2021 /PRNewswire/ -- Eucure Biopharma, a biopharmaceutical company dedicated to developing immuno-oncology antibody drugs, announced that its investigational anti-CD40 antibody drug (YH003), when combined with Junshi Biosciences anti-PD-1 antibody Toripalimab (TUOYI ®), demonstrated encouraging anti-tumor activity in an ongoing Phase I/II clinical trial in Australia. The trial is a multicenter, open label study, with an initial...

03 febbraio 2021 16:48 Fonte: Adnkronos #salute-e-benessere BOSTON and BEIJING, Feb. 3, 2021 /PRNewswire/ -- Eucure Biopharma, a biopharmaceutical company dedicated to developing immuno-oncology antibody drugs, announced that its investigational anti-CD40 antibody drug (YH003), when combined with Junshi Biosciences anti-PD-1 antibody Toripalimab (TUOYI®), demonstrated encouraging anti-tumor activity in an ongoing Phase I/II clinical trial in Australia. The trial is a multicenter, open label s...

Coherus BioSciences to Receive $50 million Strategic Investment from Immuno-Oncology Partner Junshi Biosciences REDWOOD CITY, Calif., Feb. 02, 2021 (GLOBE NEWSWIRE) -- A day after announcing their new immuno-oncology collaboration, Coherus BioSciences, Inc. (Nasdaq: CHRS) (“Coherus”) announced that Shanghai Junshi Biosciences Co., Ltd (HK: 1877; SH: 688180) (“Junshi Biosciences”) intends to make a strategic investment of $50 million in Coherus pursuant to the terms of the definitive ...

(2) REDWOOD CITY, Calif., Feb. 02, 2021 (GLOBE NEWSWIRE) -- A day after announcing their new immuno-oncology collaboration, Coherus BioSciences, Inc. (Nasdaq: CHRS) ("Coherus") announced that Shanghai Junshi Biosciences Co., Ltd (HK: 1877; SH: 688180) ("Junshi Biosciences") intends to make a strategic investment of $50 million in Coherus pursuant to the terms of the definitive stock purchase agreement. "We view our collaboration with Coherus as a strategic long-term partnership for the develo...